• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Alnylam Pharmaceuticals Inc.

    4/7/25 11:51:33 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNY alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 9)


    Alnylam Pharmaceuticals Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    02043Q107

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    02043Q107


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    100,382.00
    7Sole Dispositive Power

    12,722,314.00
    8Shared Dispositive Power

    334,291.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    13,056,605.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.03 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Alnylam Pharmaceuticals Inc
    (b)Address of issuer's principal executive offices:

    675 West Kendall Street, Cambridge, MA, 02142
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    02043Q107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    13056605
    (b)Percent of class:

    10.03  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    100382

     (iii) Sole power to dispose or to direct the disposition of:

    12722314

     (iv) Shared power to dispose or to direct the disposition of:

    334291

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:04/07/2025
    Get the next $ALNY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNY

    DatePrice TargetRatingAnalyst
    8/4/2025Underperform → Peer Perform
    Wolfe Research
    8/4/2025$490.00Perform → Outperform
    Oppenheimer
    7/30/2025$370.00Outperform
    Raymond James
    7/21/2025$385.00Buy
    Truist
    3/31/2025$353.00Buy
    Redburn Atlantic
    3/24/2025$280.00 → $328.00Neutral → Overweight
    Analyst
    11/12/2024Peer Perform → Underperform
    Wolfe Research
    10/16/2024Sector Outperform
    Scotiabank
    More analyst ratings

    $ALNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

    - Company to Webcast Investor Event on August 30, 2025, at 1:00 p.m. EDT (7:00 pm CEST)- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain, from August 29 - September 1, 2025. These presentations will highlight the potential of RNAi therapeutics to transform the treatment of cardiovascular disease and reinforce Alnylam's commitment to advancing innovative therapies for patients living with rare and more prevalent conditions underserved by

    8/11/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference, on Tuesday, August 12, 2025 at 8:00 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharmaceuticals Alnylam (NASDAQ:ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and pre

    8/5/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

    − Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – − Achieved Approximately 1,400 ATTR-CM Patients on AMVUTTRA® (vutrisiran) as of June 30, 2025 – − Obtained Approvals for AMVUTTRA for the Treatment of ATTR-CM in the European Union, Brazil, the United Kingdom and Japan – − Initiated TRITON-CM Phase 3 Trial of Nucresiran in Patients with Wild-Type or Hereditary ATTR-CM – − Raises 2025 Guidance for TTR Franchise Net Revenues to $2,175 Million to $2,275 Million; Total Net Product Revenues to $2,650 Million to $2,800 Million, Representing a $575 Mil

    7/31/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP Chief R&D Garg Pushkal was granted 2,851 shares and sold $1,299,746 worth of shares (2,851 units at $455.89) (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    8/19/25 5:28:53 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Tanguler Tolga was granted 2,851 shares and sold $632,759 worth of shares (1,396 units at $453.27), increasing direct ownership by 5% to 29,466 units (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    8/19/25 5:28:18 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Financial Officer Poulton Jeffrey V. was granted 4,644 shares and sold $1,030,727 worth of shares (2,274 units at $453.27), increasing direct ownership by 5% to 50,121 units (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    8/19/25 5:27:52 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    SEC Filings

    View All

    SEC Form 10-Q filed by Alnylam Pharmaceuticals Inc.

    10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    7/31/25 8:11:22 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    7/31/25 8:05:29 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    6/18/25 4:48:38 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Reitan Colleen F bought $10,363 worth of shares (36 units at $287.85), sold $8,383 worth of shares (36 units at $232.86) and was granted 775 shares (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    5/12/25 4:05:00 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alnylam Pharma upgraded by Wolfe Research

    Wolfe Research upgraded Alnylam Pharma from Underperform to Peer Perform

    8/4/25 8:14:44 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharma upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Alnylam Pharma from Perform to Outperform and set a new price target of $490.00

    8/4/25 8:14:34 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Alnylam Pharma with a new price target

    Raymond James resumed coverage of Alnylam Pharma with a rating of Outperform and set a new price target of $370.00

    7/30/25 7:32:36 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

    4/30/24 1:44:03 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling

    9/20/23 2:36:38 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling

    2/17/23 12:30:09 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    11/12/24 9:50:12 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    11/8/24 10:34:33 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    8/12/24 9:40:06 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Leadership Updates

    Live Leadership Updates

    View All

    Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has

    3/5/25 7:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

    As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th

    3/5/24 9:06:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Announces Appointment of Peter Kellogg to Board of Directors

    – Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. "Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to achieving our P5x25 strategy and fulfilling our ambition to become a top-tier biopharmaceutical company," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "His financial expertise and experi

    3/8/23 7:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Financials

    Live finance-specific insights

    View All

    Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

    − Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – − Achieved Approximately 1,400 ATTR-CM Patients on AMVUTTRA® (vutrisiran) as of June 30, 2025 – − Obtained Approvals for AMVUTTRA for the Treatment of ATTR-CM in the European Union, Brazil, the United Kingdom and Japan – − Initiated TRITON-CM Phase 3 Trial of Nucresiran in Patients with Wild-Type or Hereditary ATTR-CM – − Raises 2025 Guidance for TTR Franchise Net Revenues to $2,175 Million to $2,275 Million; Total Net Product Revenues to $2,650 Million to $2,800 Million, Representing a $575 Mil

    7/31/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July 31, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2025 results as well as expectations for the future via conference call on Thursday, July 31, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceuti

    7/17/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

    − Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise – − Received U.S. Food and Drug Administration (FDA) Approval of AMVUTTRA® (vutrisiran) to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) – − AMVUTTRA ATTR-CM Launch Underway with Strong Progress Across All Early Commercial Indicators – − Approval of Qfitlia™ Represents the First and Only Therapeutic to Treat Hemophilia A or B With or Without Inhibitors and the Sixth Alnylam-Discovered

    5/1/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care